Nasdaq:XTLB

XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies

Transaction Positions XTL at the Forefront of the Rapidly Expanding Global Psychedelic Therapeutics Market Following Major U.S. Regulatory Momentum Seven…

3 hours ago

XTL Biopharmaceuticals Announces ADS Ratio Change

March 20, 2026 16:10 ET  | Source: XTL Biopharmaceuticals Ltd. RAMAT GAN, ISRAEL, March 20, 2026 (GLOBE NEWSWIRE) -- XTL…

1 month ago

XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

December 24, 2025 16:00 ET  | Source: XTL Biopharmaceuticals Ltd. RAMAT GAN, ISRAEL, Dec. 24, 2025 (GLOBE NEWSWIRE) -- XTL…

4 months ago